Literature DB >> 3053234

Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi.

E G Díaz de Toranzo1, J A Castro, B M Franke de Cazzulo, J J Cazzulo.   

Abstract

Epimastigotes of Trypanosoma cruzi (Tulahuen strain Tul 0 stock) biotransform benznidazole (N-benzyl-2-nitro-1-imidazole acetamide) to reactive metabolites that bind covalently to DNA, proteins and lipids of the parasite. These effects might be related to the trypanocidal action of benznidazole, a chemotherapeutic agent against Chagas' disease.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3053234     DOI： 10.1007/BF01941187

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  18 in total

1.  Generation of superoxide anion and hydrogen peroxide induced by nifurtimox in Trypanosoma cruzi.

Authors:  R Docampo; A O Stoppani
Journal:  Arch Biochem Biophys       Date:  1979-10-01       Impact factor: 4.013

2.  Studies on the irreversible binding of 14 C-CCl 4 to microsomal lipids in rats under varying experimental conditions.

Authors:  J A Castro; M I Gomez
Journal:  Toxicol Appl Pharmacol       Date:  1972-12       Impact factor: 4.219

3.  Carbon tetrachloride target lipids in the rat liver microsomes. Effect of cystamine administration on their pattern of labeling by 14CCl4.

Authors:  M del C Villarruel
Journal:  Biochem Biophys Res Commun       Date:  1973-09-05       Impact factor: 3.575

4.  NADPH-cytochrome c reductases of Trypanosoma cruzi.

Authors:  T Kuwahara; R A White; M Agosin
Journal:  Biochem Biophys Res Commun       Date:  1984-10-15       Impact factor: 3.575

5.  Studies on pentane evolution by rats treated with nifurtimox or benznidazole.

Authors:  G D Castro; J A Castro
Journal:  Toxicology       Date:  1985-06-28       Impact factor: 4.221

Review 6.  Free radical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on Trypanosoma cruzi.

Authors:  R Docampo; S N Moreno
Journal:  Rev Infect Dis       Date:  1984 Mar-Apr

7.  Reductive metabolism and activation of benznidazole.

Authors:  M Masana; E G de Toranzo; J A Castro
Journal:  Biochem Pharmacol       Date:  1984-04-01       Impact factor: 5.858

8.  Administration of benznidazole, a chemotherapeutic agent against Chagas disease, to pregnant rats. Covalent binding of reactive metabolites to fetal and maternal proteins.

Authors:  E G de Toranzo; M Masana; J A Castro
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-11

9.  Interaction of benznidazole reactive metabolites with rat liver deoxyribonucleic acid and nuclear proteins.

Authors:  N Gorla; M I Díaz Gómez; J A Castro
Journal:  Arch Int Pharmacodyn Ther       Date:  1986-03

10.  Damage of Trypanosoma cruzi deoxyribonucleic acid by nitroheterocyclic drugs.

Authors:  S G Goijman; A C Frasch; A O Stoppani
Journal:  Biochem Pharmacol       Date:  1985-05-01       Impact factor: 5.858
View more
  15 in total

1.  Benznidazole, a drug employed in the treatment of Chagas' disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages.

Authors:  S Revelli; C Le Page; E Piaggio; J Wietzerbin; O Bottasso
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

Review 2.  Chagas disease.

Authors:  A R L Teixeira; N Nitz; M C Guimaro; C Gomes; C A Santos-Buch
Journal:  Postgrad Med J       Date:  2006-12       Impact factor: 2.401

3.  Putrescine analogue cytotoxicity against Trypanosoma cruzi.

Authors:  D Menezes; C Valentim; M F Oliveira; M A Vannier-Santos
Journal:  Parasitol Res       Date:  2005-11-11       Impact factor: 2.289

4.  Putative Role of the Aldo-Keto Reductase from Trypanosoma cruzi in Benznidazole Metabolism.

Authors:  Patricia Andrea Garavaglia; Marc Laverrière; Joaquín J B Cannata; Gabriela Andrea García
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  CYP51: A major drug target in the cytochrome P450 superfamily.

Authors:  Galina I Lepesheva; Tatyana Y Hargrove; Yuliya Kleshchenko; W David Nes; Fernando Villalta; Michael R Waterman
Journal:  Lipids       Date:  2008-09-04       Impact factor: 1.880

6.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Authors:  D E Perez-Mazliah; M G Alvarez; G Cooley; B E Lococo; G Bertocchi; M Petti; M C Albareda; A H Armenti; R L Tarleton; S A Laucella; R Viotti
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

7.  Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment.

Authors:  Paola Carolina Bazán; María Silvina Lo Presti; Héctor Walter Rivarola; María Fernanda Triquell; Ricardo Fretes; Alicia Ruth Fernández; Julio Enders; Patricia Paglini-Oliva
Journal:  Parasitol Res       Date:  2008-05-31       Impact factor: 2.289

8.  Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics.

Authors:  Andrea Trochine; Darren J Creek; Paula Faral-Tello; Michael P Barrett; Carlos Robello
Journal:  PLoS Negl Trop Dis       Date:  2014-05-22

9.  Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi.

Authors:  V Michailowsky; S M Murta; L Carvalho-Oliveira; M E Pereira; L R Ferreira; Z Brener; A J Romanha; R T Gazzinelli
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Soulamarin isolated from Calophyllum brasiliense (Clusiaceae) induces plasma membrane permeabilization of Trypanosoma cruzi and mytochondrial dysfunction.

Authors:  Alexandre Rea; Andre G Tempone; Erika G Pinto; Juliana T Mesquita; Eliana Rodrigues; Luciana Grus M Silva; Patricia Sartorelli; João Henrique G Lago
Journal:  PLoS Negl Trop Dis       Date:  2013-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.